Regulatory GSK again pulls application for leucovorin, touted by FDA as potential autism treatment BioSpaceGSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to...RegulatoryNeuroscienceRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) BioSpace GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to… RegulatoryNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Roche places a $1bn bet on C4T degrader-antibody conjugatesNext: Senju launches first-in-class dry eye disease drug in Japan Related Stories Regulatory Japan approves Sanofi’s Sarclisa combo for MM treatment pharminent June 22, 2026 Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot pharminent June 19, 2026 Regulatory Moderna flu vaccine wins unanimous support from FDA panel pharminent June 18, 2026
